The present invention provides compositions having synergistic antioxidant properties in the modulation of Toll-like receptor signaling for the promotion of homeostasis, immunity, energy conservation, protection of neural cells and anti-inflammatory responses, said compositions comprising plant and/or fruit extracts and a natural sweetener with high oxidation potential as defined by ORAC value.

The present invention provides compositions having synergistic antioxidant properties in the modulation of Toll-like receptor signaling for the promotion of homeostasis, immunity, energy conservation, protection of neural cells and anti-inflammatory responses, said compositions comprising plant and/or fruit extracts and a natural sweetener with high oxidation potential as defined by ORAC value.

An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach.

An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach.

The present invention relates to oriental medicine compositions marked as SEC 22 and SEC 33 for improving digestive functions and respiratory functions for improving children's underweight, low growth and depressed respiratory organ, an oriental medicine derived therefrom, and methods of preparing them. According to an example of the present invention, the oriental medicine composition containing broiled fruit of Crataegus pinnatifida, broiled root of Atractylodes japonica, dried peel of Citrus unshiu, broiled sprout of Hordeum vulgare, broiled fruit of Amomum xanthioides, root of Zingiber officinale, dried fruit of Zizyphi, and horn of Cervus elaphus.

The present invention relates to oriental medicine compositions marked as SEC 22 and SEC 33 for improving digestive functions and respiratory functions for improving children's underweight, low growth and depressed respiratory organ, an oriental medicine derived therefrom, and methods of preparing them. According to an example of the present invention, the oriental medicine composition containing broiled fruit of Crataegus pinnatifida, broiled root of Atractylodes japonica, dried peel of Citrus unshiu, broiled sprout of Hordeum vulgare, broiled fruit of Amomum xanthioides, root of Zingiber officinale, dried fruit of Zizyphi, and horn of Cervus elaphus.

The present invention relates to oriental medicine compositions marked as SEC 22 and SEC 33 for improving digestive functions and respiratory functions for improving children's underweight, low growth and depressed respiratory organ, an oriental medicine derived therefrom, and methods of preparing them. According to an example of the present invention, the oriental medicine composition containing broiled fruit of Crataegus pinnatifida, broiled root of Atractylodes japonica, dried peel of Citrus unshiu, broiled sprout of Hordeum vulgare, broiled fruit of Amomum xanthioides, root of Zingiber officinale, dried fruit of Zizyphi, and horn of Cervus elaphus.

An embodiment of the present invention provides an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, including: an ephedra powder agent of which ephedrine content is concentrated to be 3.0 to 4.0%, which is greater than 0.5 to 2.5% when it is in a natural state, and of which the ephedrine content is maintained constant at 3.0 to 4.0%; and a side-effect-preventing powder agent for each constitution prescribed based on Sasang constitutional medicine in order to prevent a side effect of the ephedra powder agent, wherein a weight ratio of the ephedra powder agent and the side-effect-preventing powder agent is 8-10:1 to 9-11:1.

An embodiment of the present invention provides an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, including: an ephedra powder agent of which ephedrine content is concentrated to be 3.0 to 4.0%, which is greater than 0.5 to 2.5% when it is in a natural state, and of which the ephedrine content is maintained constant at 3.0 to 4.0%; and a side-effect-preventing powder agent for each constitution prescribed based on Sasang constitutional medicine in order to prevent a side effect of the ephedra powder agent, wherein a weight ratio of the ephedra powder agent and the side-effect-preventing powder agent is 8-10:1 to 9-11:1.

A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.